![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Meerbach Astrid Gruhn Bernd Wutzler Peter
Publisher: Informa Healthcare
ISSN: 1354-3776
Source: Expert Opinion on Therapeutic Patents, Vol.14, Iss.4, 2004-04, pp. : 527-547
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Ciclosporin: Epstein-Barr virus-associated lymphoproliferative disorder: case report
Reactions Weekly, Vol. 1, Iss. 1047, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Infliximab: Epstein-Barr virus associated lymphoproliferative disorder: case report
Reactions Weekly, Vol. 1, Iss. 1283, 2010-01 ,pp. :